Luye Pharma Group Ltd - Asset Resilience Ratio

Latest as of June 2025: 5.92%

Luye Pharma Group Ltd (LUP) has an Asset Resilience Ratio of 5.92% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Luye Pharma Group Ltd (LUP) total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

€1.90 Billion
≈ $2.22 Billion USD Cash + Short-term Investments

Total Assets

€32.03 Billion
≈ $37.45 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how Luye Pharma Group Ltd's Asset Resilience Ratio has changed over time. See LUP total equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Luye Pharma Group Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Luye Pharma Group Ltd worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €1.90 Billion 5.92%
Total Liquid Assets €1.90 Billion 5.92%

Asset Resilience Insights

  • Limited Liquidity: Luye Pharma Group Ltd maintains only 5.92% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Luye Pharma Group Ltd Industry Peers by Asset Resilience Ratio

Compare Luye Pharma Group Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
Drug Manufacturers - Specialty & Generic 0.16%
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Drug Manufacturers - Specialty & Generic 1.54%
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Drug Manufacturers - Specialty & Generic 0.20%
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
Drug Manufacturers - Specialty & Generic 43.05%
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
Drug Manufacturers - Specialty & Generic 20.44%
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
Drug Manufacturers - Specialty & Generic 24.59%
Henan Newland Pharmaceutical Co. Ltd. A
SHE:301277
Drug Manufacturers - Specialty & Generic 31.63%
Hainan Shuangcheng Pharmaceut
SHE:002693
Drug Manufacturers - Specialty & Generic 3.29%

Annual Asset Resilience Ratio for Luye Pharma Group Ltd (2016–2024)

The table below shows the annual Asset Resilience Ratio data for Luye Pharma Group Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 5.29% €1.57 Billion
≈ $1.83 Billion
€29.61 Billion
≈ $34.62 Billion
-5.96pp
2023-12-31 11.25% €2.87 Billion
≈ $3.35 Billion
€25.49 Billion
≈ $29.80 Billion
-2.03pp
2022-12-31 13.28% €3.22 Billion
≈ $3.77 Billion
€24.25 Billion
≈ $28.35 Billion
-0.32pp
2021-12-31 13.60% €3.07 Billion
≈ $3.59 Billion
€22.58 Billion
≈ $26.40 Billion
+6.13pp
2020-12-31 7.47% €1.54 Billion
≈ $1.80 Billion
€20.63 Billion
≈ $24.12 Billion
-7.35pp
2019-12-31 14.82% €2.86 Billion
≈ $3.35 Billion
€19.31 Billion
≈ $22.58 Billion
-3.36pp
2018-12-31 18.19% €3.19 Billion
≈ $3.73 Billion
€17.54 Billion
≈ $20.50 Billion
-5.75pp
2017-12-31 23.93% €2.58 Billion
≈ $3.01 Billion
€10.76 Billion
≈ $12.58 Billion
-1.59pp
2016-12-31 25.52% €2.35 Billion
≈ $2.75 Billion
€9.21 Billion
≈ $10.76 Billion
--
pp = percentage points

About Luye Pharma Group Ltd

F:LUP Germany Drug Manufacturers - Specialty & Generic
Market Cap
$1.26 Billion
€1.08 Billion EUR
Market Cap Rank
#8416 Global
#1090 in Germany
Share Price
€0.27
Change (1 day)
-1.46%
52-Week Range
€0.21 - €0.48
All Time High
€0.70
About

Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People's Republic of China, the United States, Europe, and internationally. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and X… Read more